Answers are grounded in this paper and cite their sources.
Natural products occupy structural and physicochemical space that is poorly represented by optimization criteria developed for conventional small molecules. We developed SWAN-MPO, a multi-parameter framework that integrates predicted target binding, absorption/distribution/metabolism/excretion (ADME) properties, general safety, and disease-context liabiliy for natural-product scaffold triage. Receptor-specific docking calibration and bounded desirability transformations place heterogeneous evidence on a common decision scale before cross-domain integration. Applied to 59 Annona muricata compounds across nine oncology targets, SWAN-MPO substantially changed candidate prioritization by favoring balanced cross-domain profiles. External ChEMBL benchmarking revealed why this matters: binding almost perfectly distinguished active from inactive compounds (ROC-AUC 0.976) but was essentially uninformative for separating favorable from serious-warning profiles among already-active compounds (ROC-AUC 0.503), where ADME was more discriminative (ROC-AUC 0.620). On the combined activity/status endpoint, the integrated formulation achieved ROC-AUC 0.909. In a separate descriptor-compatible benchmark, SWAN-MPO significantly outperformed four adapted multiparameter and drug-likeness comparators in global discrimination. These results show that natural-product prioritization depends on integrating property domains that answer different screening questions rather than optimizing any single signal.
No takes yet. Share an insight, caveat, or question.
Saanvii Senthilkumar (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: